Baird analyst Jack Allen has maintained an Outperform rating for Taysha Gene Therapies, citing a revised valuation. The firm increased its price target for the company to $15, up from the previous target of $12.

Rating and Price Target Details

The decision to raise the price target reflects a more optimistic outlook on the stock's potential. The Outperform rating suggests that the stock is expected to perform better than the market average.

Taysha Gene Therapies, Inc. announced multiple presentations highlighting its TSHA-102 program for Rett syndrome at the 2026 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting held in Prior Lake, MN, from June 29 to July 1, 2026. The company disclosed that recently revealed longer-term data from the REVEAL Part A trial demonstrated a broad, multi-domain functional impact that deepened over time through at least 12 months post-treatment, regardless of age or disease severity. Additionally, a natural history data analysis indicated a clear developmental plateau after 6 years of age, supporting a stable population for the ongoing REVEAL pivotal trial.

Clinical and Preclinical Findings

The presentations included safety and efficacy results from the REVEAL Part A Phase 1/2 trial in pediatric and adolescent/adult cohorts, delivered by Principal Investigator Elsa Rossignol, M.D. New data supported the Rett Syndrome Developmental Milestone Assessment (RS-DMA) as a psychometrically valid, FDA-supported primary endpoint for single-arm interventional studies. Preclinical findings demonstrated superior MeCP2 expression of self-complementary AAV9 compared to single-stranded vectors, supporting effective central nervous system delivery via intrathecal administration.

About TSHA-102

TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy designed as a one-time treatment to address the genetic root cause of Rett syndrome. It delivers a functional form of MECP2 to cells in the central nervous system utilizing miRNA-Responsive Auto-Regulatory Element (miRARE) technology to mediate expression levels without risk of overexpression. TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, as well as Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.